Trial Profile
Safety, tolerability and pharmacokinetics of Cannabidiol oral solution in healthy adult volunteers, A Phase I, randomized, Double-Blind, Placebo-Controlled trial
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 02 Feb 2019
Price :
$35
*
At a glance
- Drugs Cannabidiol (Primary)
- Indications Cerebral ischaemia; Dravet syndrome; Duchenne muscular dystrophy; Epilepsy; Infantile spasms; Lennox-Gastaut syndrome; Opioid-related disorders; Ovarian cancer; Parkinson's disease; Schizophrenia; Tuberous sclerosis
- Focus Adverse reactions
- 04 Dec 2018 Results assessing the safety, tolerability, and pharmacokinetics (PK) of this formulation of CBD in healthy volunteers, as well as the effects of food on exposure, presented at the 72nd Annual Meeting of the American Epilepsy Society.
- 18 Nov 2018 New trial record
- 30 Oct 2018 Results published in the CNS Drugs